Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • January 2023
  • Case
  • HBS Case Collection

Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker
  • Format:Print
  • | Language:English
  • | Pages:24
ShareBar

Abstract

What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful therapy was on track but faced an unclear future. Overseeing the human trials of a refined second-generation drug candidate, Amy had led the company back from the “valley of death” after Cleave’s initial offering resulted in off-target toxicity. Still, after completing multiple dose escalation cohorts, Cleave’s scientists told Amy that they could not draw any definitive conclusions about the benefits of the drug. Amy and her team knew the importance of speed and capital in the high-risk business of oncology drug development where success often takes more resources and time than expected and competitors lurk. Nearing the close of a five-year investment window, should the thinly staffed Cleave 2.0 continue to recruit patients and clear dosing cohorts at a rapid rate, or should Amy prioritize funding and partnership discussions?

This case is suitable as a general business case for undergraduate and MBA students of any level on strategy, entrepreneurship, health care innovation, biopharma, cancer, FDA’s role in biopharma, funding early-stage biopharma ventures, biopharma clinical trials, and the healthcare industry.

Keywords

Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry

Citation

Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
  • Educators
  • Purchase

About The Author

Regina E. Herzlinger

General Management
→More Publications

More from the Authors

    • 10 Dec 2024
    • Faculty Research

    A New Model for Funding Healthcare Innovation

    By: Regina E. Herzlinger and Duke Rohlen
    • October 2024
    • Faculty Research

    Parexel: Scaling Up and Industry Dynamics

    By: Regina E. Herzlinger and Ben Creo
    • September 2024 (Revised March 2025)
    • Faculty Research

    Epic: The Future of Health Information Technology

    By: Regina E. Herzlinger and Brian L. Walker
More from the Authors
  • A New Model for Funding Healthcare Innovation By: Regina E. Herzlinger and Duke Rohlen
  • Parexel: Scaling Up and Industry Dynamics By: Regina E. Herzlinger and Ben Creo
  • Epic: The Future of Health Information Technology By: Regina E. Herzlinger and Brian L. Walker
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.